SEC Company Response from Biodexa Pharmaceuticals Plc (BDRX) (CIK 0001643918) (BDRX) — Oct 17, 2019
Biodexa Pharmaceuticals Plc (BDRX) (CIK 0001643918)
Date: Oct. 17, 2019 · CIK: 0001643918 · Accession: 0001214659-19-006516
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-233901
Letter
Midatech Pharma PLC
Oddfellows House
19 Newport Road
Cardiff, CF24 0AA
United Kingdom
October 17, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Donald Field
Re:
Midatech Pharma PLC
Registration Statement on Form F-3, as amended (File No. 333-233901)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Midatech Pharma PLC hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form F-3 (as amended to date, the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m., Eastern Time, on October 21, 2019, or as soon as practicable thereafter.
[Signature Page Follows]
Very truly yours,
MIDATECH PHARMA PLC
Show Raw Text
CORRESP
1
filename1.htm
Midatech Pharma PLC
Oddfellows House
19 Newport Road
Cardiff, CF24 0AA
United Kingdom
October 17, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Donald Field
Re:
Midatech Pharma PLC
Registration Statement on Form F-3, as amended (File No.
333-233901)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended, Midatech Pharma PLC
hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced
Registration Statement on Form F-3 (as amended to date, the “Registration Statement”) and declare the Registration
Statement effective as of 4:00 p.m., Eastern Time, on October 21, 2019, or as soon as practicable thereafter.
[Signature Page Follows]
Very truly yours,
MIDATECH PHARMA PLC
By: /s/ Stephen Stamp
Name: Stephen Stamp
Title: Chief Financial Officer